Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;64(4):719-724.
doi: 10.1111/ijd.17520. Epub 2024 Nov 3.

LC-OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to histopathology

Affiliations

LC-OCT for early diagnosis and characterization of dermatologic adverse events to oncologic drugs and correlation to histopathology

Pietro Sollena et al. Int J Dermatol. 2025 Apr.

Abstract

Background: Targeted and immune therapies have recently been associated with the occurrence of multiple cutaneous toxicities, often challenging to differentiate by clinical examination alone without histology. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive and innovative imaging technique that has been shown to be almost as effective as histology in diagnosing several skin conditions. Our study aimed to assess the effectiveness of LC-OCT in predicting the clinical evolution of early maculopapular eruptions related to antineoplastic targeted therapy and immunotherapy.

Methods: In the period between May 2023 and December 2023, consecutive patients with clinical cutaneous maculopapular reactions caused by oncologic targeted therapy or immunotherapy were enrolled at the dermatologic outpatient clinic of the Fondazione Policlinico A. Gemelli IRCCS, Rome. Patients underwent clinical dermatological examination, video-dermoscopy, LC-OCT, and incisional skin biopsy of a target cutaneous lesion. To investigate the evolutionary pattern of maculopapular lesions (psoriasic eruption, lichenoid eruption, eczematous eruption, bullous eruption), LC-OCT and histopathological images have been compared based on specific characteristics (hyperkeratosis, acanthosis, spongiosis; papillomatosis; lichenoid inflammatory infiltrate; presence of intraepidermal/subepidermal cleavage plan with formation of a bulla).

Results: Eighteen patients were included in this study (11 males, 7 females, median age 64.5). LC-OCT demonstrated an overall concordance with histology of 77.8%, with a Cohen's Kappa of 0.69 (P < 0.0001). Sensitivity exceeded 70%, and specificity was ≥88.2%. The Area Under the Curve (AUC) ranged from 0.9 to 1 for psoriasis and lichenoid eruption and from 0.7 to 0.9 for eczematous and bullous eruption.

Conclusions: LC-OCT appears to be a promising tool for the early differential diagnosis of adverse skin reactions related to targeted therapy and immunotherapy, offering the potential to avoid skin biopsies in fragile cancer patients.

Keywords: cutaneous adverse events; histopathology; line‐field confocal optical coherence tomography; oncologic treatments.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a, d, g) Clinical pictures of cutaneous maculopapular lesions of the trunk differentiated based on LC‐OCT vertical views and histopathologic findings, hematoxylin and eosin (H&E) stain 10×: (b) psoriatic eruption with LC‐OCT features of hyperkeratosis (yellow vertical line), acanthosis (red vertical line) and papillomatosis (red asterisks), (c) histopathology of the psoriatic lesion showing comparable LC‐OCT features; (e) eczematous eruption on the chest revealing LC‐OCT findings of pronounced hyperkeratosis (yellow line), spongiosis (yellow circle) and basal vacuolar degeneration (red arrows) (f) as seen in histopathology; (h) lichenoid eruption of the chest exhibiting clusters of inflammatory cells at the junction (red dotted circle), (i) as typical and better assessed in the pathological slide

References

    1. Belloni B, Schönewolf N, Rozati S, Goldinger SM, Dummer R. Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy. 2012;97:191–202. - PubMed
    1. Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol. 2013;9(8):1161–1170. 10.2217/fon.13.62 - DOI - PubMed
    1. Sollena P, Cappilli S, Federico F, Schinzari G, Tortora G, Peris K. “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. Hum Vaccin Immunother. 2022;18(3):1889449. 10.1080/21645515.2021.1889449 - DOI - PMC - PubMed
    1. Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract. 2014;2014:734249. - PMC - PubMed
    1. Sollena P, Mannino M, Tassone F, Calegari MA, D'Argento E, Peris K. Efficacy of topical beta‐blockers in the management of EGFR‐inhibitor induced paronychia and pyogenic granuloma‐like lesions: case series and review of the literature. Drugs Context. 2019;(8):212613. 10.7573/dic.212613 - DOI - PMC - PubMed

Substances

LinkOut - more resources